AZD2932 NEW
| Price | $33 | $53 | $98 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-04-29 |
Product Details
| Product Name: AZD2932 | CAS No.: 883986-34-3 |
| Purity: 97.71% | Supply Ability: 10g |
| Release date: 2025/04/29 |
Product Introduction
Bioactivity
| Name | AZD2932 |
| Description | AZD2932 is a potent, multi-targeted kinase inhibitor of VEGFR2, PDGFβ, Flt-3, and c-Kit. |
| Kinase Assay | Kinase Assays : In vitro kinase IC50 values are measured using 33P filtration binding assay after 1 hour incubation of kinase, 33P-ATP, Ibrutinib, and substrate [0.2 mg/mL poly(EY)(4:1]. Assays are performed at Reaction Biology. |
| In vitro | In the C6 rat glioma model, oral administration of AZD2932 (12.5 or 50 mg/kg, b.i.d.) was able to inhibit tumor growth. Additionally, in xenografts with tumors not expressing PDGFβ, oral doses of AZD2932 (50 mg/kg, b.i.d.) succeeded in suppressing the growth of Calu-6 and LoVo tumors. |
| In vivo | AZD2932 effectively inhibits the phosphorylation of PDGFRα and PDGFRβ, demonstrating strong activity against a variety of receptors including VEGFR-2 (IC50=8 nM), PDGFRβ (IC50=4 nM), Flt-3 (IC50=7 nM), and c-Kit (IC50=9 nM). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 82 mg/mL (183.24 mM), Sonication is recommended. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : 5 mg/mL (11.17 mM), Heating is recommended. |
| Keywords | VEGFR2 | VEGFR | Vascular endothelial growth factor receptor | SCFR | Platelet-derived growth factor receptor | PDGFRβ | PDGFR | Inhibitor | inhibit | Fms like tyrosine kinase 3 | FLT3 | Cluster of differentiation antigen 135 | c-Kit | cKit | CD135 | CD117 | AZD-2932 | AZD2932 | AZD 2932 |
| Inhibitors Related | Ribociclib | Gilteritinib | Nintedanib | Regorafenib monohydrate | Sorafenib | Pexidartinib | Regorafenib | Sorafenib tosylate | Lenvatinib mesylate | Imatinib | Pazopanib | Axitinib |
| Related Compound Libraries | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Hematonosis Compound Library | Inhibitor Library | Anti-Prostate Cancer Compound Library | Anti-Fibrosis Compound Library | NO PAINS Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $/ |
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY